A 60-year-old woman who has felt sad for much of her life

JAMA

Volumn 295, Issue 3, 2006, Pages 318-323

  Salzman, Carl ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CALCIUM; CLONAZEPAM; CLOPIDOGREL; ESOMEPRAZOLE; TRIAMTERENE; WARFARIN;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DOCTOR PATIENT RELATION; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MEMORY DISORDER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SOCIAL WORKER; TREATMENT RESISTANT DEPRESSION;

EID: 30944447322     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.3.318     Document Type: Review

References (52)

1. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649-659.
2. Manning JS. Difficult-to-treat depressions: a primary care perspective. J Clin Psychiatry. 2003;64:24-31.
3. Corey-Lisle PK, Nash R, Stang P, Swindle R. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med. 2004;164:1197-1204.
4. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry. 1985;142:430-436.
5. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry. 1993;54:338-342.
6. Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003;53:680-690.
7. Rothschild AJ, Duval SE. How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry. 2003;64:390-396.
8. Fink M. A trial of ECT is essential before a diagnosis of refractory depression is made. In: Amsterdam JD, ed. Advances in Neuropsychiatry and Psychopharmacology, Volume 2: Refractory Depression. New York, NY: Raven Press; 1991:87-92.
9. Iosifescu DV, Nierenberg AA, Alpert JE, et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry. 2003;160:2122-2127.
10. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry. 2003;53:640-648.
11. Keitner GI, Ryan CE, Miller IW, et al. 12-Month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry. 1991;148:345-350.
12. Oslin DW, Datto CJ, Kallan MJ, et al. Association between medical comorbidity and treatment outcomes in late-life depression. J Am Geriatr Soc. 2002;50:823-828.
13. Small GW, Birkett M, Meyers BS, et al. Impact of physical illness on quality of life and antidepressant response in geriatric major depression. J Am Geriatr Soc. 1996;44:1220-1225.
14. Iosifescu DV, Nierenberg AA, Alpert JE, et al. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. Psychosomatics. 2004;45:419-425.
15. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry. 2001;62:26-31.
16. Papakostas GI, Petersen T, Denninger J, et al. Somatic symptoms in treatmentresistant depression. Psychiatry Res. 2003;118:39-45.
17. Fava M. Depression with physical symptoms: treating to remission. J Clin Psychiatry. 2003;64:24-28.
18. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54:317-329.
19. Goodnick PJ. Use of antidepressant in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry. 2001;13:31-41.
20. Lesperance F, Frasure-Smith N. Depression in patients with cardiac disease: a practical review. J Psychosom Res. 2000;48:379-391.
21. Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry. 1998;155:660-665.
22. Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry. 2003;54:376-387.
23. Miller MD, Lenze EJ, Dew MA, et al. Effect of cerebrovascular risk factors on depression treatment outcome in later life. Am J Geriatr Psychiatry. 2002;10:592-598.
24. Evans M, Hammond M, Wilson K, et al. Placebo-controlled treatment trial of depression in elderly physically ill patients. Int J Geriatr Psychiatry. 1997;12:817-824.
25. Papakostas GI, Petersen T, Iosifescu DV, et al. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res. 2003;118:183-188.
26. Worthington J, Fava M, Agustin C, et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients: relationship with response to treatment. Psychosomatics. 1996;37:518-522.
27. Castaneda R, Sussman N, Westreich L, et al. A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. J Clin Psychiatry. 1996;57:207-212.
28. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62:18-25.
29. Bosworth HB, McQuoid DR, George LK, Steffens DC. Time-to-remission from geriatric depression: psychosocial and clinical factors. Am J Geriatr Psychiatry. 2002;10:551-559.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994:629-674.
31. Hirschfeld RM, Russell JM, Delgado PL, et al. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry. 1998;59:669-675.
32. Thase ME. The role of Axis II comorbidity in the management of patients with treatment-resistant depression. Psychiatr Clin North Am. 1996;19:287-309.
33. Newman JR, Ewing SE, McColl RD, et al. Tridimensional personality questionnaire and treatment response in major depressive disorder: a negative study. J Affect Disord. 2000;57:241-247.
34. Van Praag HM. Crossroads of corticotropin releasing hormone, corticosteroids and monoamines: about a biological interface between stress and depression. Neurotox Res. 2002;4:531-555.
35. Katzir G, Datto CJ, Weintraub D, Oslin DW. Diagnosis of late-life depression. In: Salzman C, ed. Clinical Geriatric Psychopharmacology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:212-213.
36. Baldwin RC, Simpson S. Treatment resistant depression in the elderly: a review of its conceptualisation, management and relationship to organic brain disease. J Affect Disord. 1997;46:163-173.
37. Alexopoulos G. Depression in the elderly. Lancet. 2005;365:1961-1970.
38. Alexopoulos GS. Vascular disease, depression, and dementia. J Am Geriatr Soc. 2003;51:1178-1180.
39. Figiel GS, Krishnan KR, Doraiswamy PM, et al. Subcortical hyperintensities on brain magnetic resonance imaging: a comparison between late age onset and early onset elderly depressed subjects. Neurobiol Aging. 1991;12:245-247.
40. Fujikawa T, Yokota N, Muraoka M, Yamawaki S. Response of patients with major depression and silent cerebral infarction to antidepressant drug therapy, with emphasis on central nervous system adverse reactions. Stroke. 1996;27:2040-2042.
41. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
42. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509-522.
43. Yu YW, Tsai SJ, Chen TJ, et al. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry. 2002;7:1115-1119.
44. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry. 2000;61:10-12.
45. Zajecka JM. Treating depression to remission. J Clin Psychiatry. 2003;64:7-12.
46. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull. 1992;28:253-256.
47. Joffe RT, Levitt AJ, Sokolov ST, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996;57:114-115.
48. Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry. 2003;64:5-12.
49. Bauer M, Adli M, Baethge C, et al. Lithium augmentation therapy and refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry. 2003;48:440-448.
50. Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression. Arch Gen Psychiatry. 2004;61:714-719.
51. Salzman C, Bemporad J. Combined psychotherapeutic and psychopharmacologic treatment of depressed patients: Clinical observations. In: DW Manning, AJ Francis. Combination Psychiatry and Psychotherapy in Depression. Arlington, Va: APA Press; 1990:152-181.
52. Wei W, Sambamoorthi U, Olfson M, Walkup JT, Crystal S. Use of psychotherapy for depression in older adults. Am J Psychiatry. 2005;162:711-717.